This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Enzo Therapeutics, Inc.. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: Bertrand Huard: Innovator in Lymphoma Prognosis
Introduction
Bertrand Huard is a notable inventor based in Juvigny, France. He has made significant contributions to the field of medical research, particularly in the area of lymphoma prognosis. His innovative work has led to the development of a unique patent that addresses critical challenges in cancer treatment.
Latest Patents
Huard holds a patent for "Antibodies against APRIL as biomarkers for early prognosis of lymphoma patients." This invention relates to antibodies directed against APRIL (A Proliferation Inducing TNF Ligand, also known as TALL-2). Specifically, it includes the monoclonal antibody Aprily-2, hybridoma cells producing this antibody, and the use of a combination of an antibody against membrane-anchored APRIL and Aprily-2. This combination is crucial for diagnosing B cell lymphoma resistance to treatment and for predicting the clinical development of Diffuse Large B-Cell (DLBCL) lymphoma in high-risk patients, particularly those over 60 years old with an International Prognostic Index greater than 2. Additionally, the patent describes an amino acid sequence GTGGPSQNGEGYP, referred to as Stalk, which is useful in the preparation of antibodies.
Career Highlights
Throughout his career, Huard has worked with various organizations that focus on biotechnology and medical research. Notably, he has been associated with Enzo Therapeutics, Inc. and Enzo Life Sciences. His work in these companies has contributed to advancements in therapeutic solutions and diagnostic tools.
Collaborations
Huard has collaborated with several professionals in his field, including Lars French and Olivier Donze. These partnerships have enhanced his research and development efforts, leading to innovative solutions in lymphoma prognosis.
Conclusion
Bertrand Huard's contributions to the field of lymphoma research through his patent on antibodies against APRIL highlight his role as an innovator in medical science. His work continues to impact the diagnosis and treatment of lymphoma patients, showcasing the importance of innovation in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile